ANA
Ananda Developments Plc
Access
ISIN
GB00BDQPXQ60
Bid
0.53
Mid
0.56
Ask
0.58
Key Information
- Price Change
- 0.00%
- Year High
- 0.72
- Year Low
- 0.28
- Last Trade
- 6 Jun 23
- Market Cap
- £15.95M
- Par
- 0.20
- Bid
- 0.53
- Mid Price
- 0.56
- Ask
- 0.58
- Instrument Type
- Ordinary Shares
- MIFID Status
- MTF
- Tradable Securities
- 2.874B
- Sector
- Healthcare
Prices in GBX except for Market Cap in GBP
About Ananda Developments Plc
Ananda’s mission is to become a leading UK grower and provider of high quality, consistent medical cannabis for the UK and international markets. What is the opportunity for cannabis medicines? The world has an increasing problem with hard to treat complex and chronic inflammatory pain conditions such as fibromyalgia, neuropathic pain, rheumatology, endometriosis, epilepsy. •The anti-inflammatory therapeutics market is expected to be worth USD 127.5bn by 2030 •0%-51.3% of UK population suffers from chronic inflammatory pain (approximately 28 million people). •NHS spends more than £5bn pa on treating and trying to treat these conditions. •Massive increase in amount of research into cannabis, cannabinoids, CBD, endocannabinoid system. •Research increasingly demonstrating cannabis and its constituents are very good at treating complex chronic inflammatory pain conditions. •Increasing number of medical cannabis patients and prescriptions in the UK and globally. •Increased recognition of cannabis by UK regulators (first UK based MHRA certified GMP manufacturing facility, NICE (National Institute for Clinical Excellence) calls for research and evidence). Through both of its wholly owned subsidiaries, DJT Plants Limited (cultivation) and MRX Medical Limited (cannabis oil formulation and manufacturing), Ananda intends to target these indications. The impact of Ananda as a UK cultivator and manufacturer will be significant: •The highest quality cannabis medicines, grown and formulated in the UK to the highest UK standards, at low cost •The shortest supply chain to ensure patients won’t run out of medicine •UK research with UK cannabis medicines to give confidence to prescribers and regulators •The team to deliver: a combination of seasoned, successful and driven entrepreneurs together with best-in-class scientists, cultivators and go to market specialists. At our dedicated cultivation facility in the UK, we are currently working through medical cannabis strain stabilisation research and scaled cultivation trials in readiness for our application to grow for commercial purposes to meet the needs of UK patients and prescribers. Via partnership with the University of Edinburgh, MRX is actively involved in two of the first ever Phase II randomised control trials using CBD as the active pharmaceutical ingredient.
Latest Trades
Date | Volume | Price (GBX) | Value (GBP) |
---|---|---|---|
06 Jun 23 12:29 | 115,852 | 0.56 | 648.77 |
06 Jun 23 09:15 | 593,791 | 0.58 | 3,443.99 |
05 Jun 23 15:47 | 23,647 | 0.53 | 125.33 |
02 Jun 23 13:45 | 132 | 0.52 | 0.69 |
02 Jun 23 09:56 | 38,910 | 0.55 | 214.01 |
Latest Announcements
Date | Title |
---|---|
17 May 23 07:00 | Ananda Developments - Patent Applications Filed |
15 May 23 07:00 | Ananda Developments - Appointment of AQSE Corporate Adviser and Broker |
10 May 23 09:00 | Ananda Developments - Research Round Up |
05 May 23 10:26 | Ananda Developments Plc - Shareholder Update, CLN Redemption, Warrant Exercise |
28 Apr 23 14:09 | Ananda Developments Plc - Total Voting Rights |
Address
Registered Address
PLC 6th Floor, 60 Gracechurch Street, London, EC3V 0HR, United Kingdomir@anandadevelopments.com
Phone
+44 7392 696517
Contacts
Corporate Adviser
Peterhouse Capital Ltd, 3rd Floor, 80 Cheapside, London, EC2V 6EE, United KingdomRegistrar
SLC Registrars, P.O. Box 5222, Lancing, BN99 9FG, United Kingdom